Please select the option that best describes you:
How, if at all, does the spectrum of HER2 positivity impact efficacy of T-DXd in the frontline setting?
Does T-DXd overcome the disparity in response to other HER2 directed therapies between HER2 2+ and 3+ disease? Should HER2 expression levels be a consideration for T-DXd use as a frontline therapy?
Answer from: Medical Oncologist at Academic Institution
Multiple studies have shown that HER2 3+ disease is a predictor for exceptional (long-term) response to first-line THP, and conversely, patients with HER2 2+/FISH positive disease are less likely to experience an exceptional response to THP. While I have not seen a subset analysis by HER2 2+ vs 3+ p...
Sign In or Register to read more